TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Jia Xiang Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.